CVC, Temasek 'exploring options' for Alvogen
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Hong Kong
ALVOGEN'S owners - including CVC Capital Partners and Temasek Holdings - are said to be exploring options for the generic pharmaceutical company, which could be valued at about US$4 billion, according to people familiar with the matter.
The controlling shareholders of the drugmaker have held on-and-off talks with Shanghai Pharmaceuticals Holding Co focusing on a sale of Alvogen's US business, the people said. Alvogen would keep its operations in Asia as well as central and eastern Europe, one of the people said.
Share with us your feedback on BT's products and services
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
